Junshi wins the race for first made-in-China PD-1 approval as execs reap $394M IPO harvest
It’s been a big day for Junshi Biosciences as it nabs China’s first snap approval for a homegrown PD-1 after reportedly closing a $394 million IPO in Hong Kong.
Conditionally approved under priority review, toripalimab is indicated for fast-growing cases of melanoma, according to the National Medical Products Administration.
“Clinical trial results of this product shows that in treating patients with unresectable or metastatic melanoma who have failed previous systemic therapies, it reaches an objective response rate of 17.3%, disease control rate of 57.5%, and 1-year survival rate of 69.3%,” the NMPA writes in a note. “The product’s marketing approval has a positive impact on the selection of clinical drugs for cancer patients.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.